GlaxoSmithKline: ViiV Healthcare to Present Data for Its Next Generation of Ultra Long-Acting Treatments for HIV
February 29, 2024
February 29, 2024
LONDON, England, Feb. 29 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on Feb. 28, 2024:
GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of 64 abstracts that includes highlights of the company's next-generation pipeline advancements, alongside data from its diverse portfolio of marketed HIV treatment and . . .
GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of 64 abstracts that includes highlights of the company's next-generation pipeline advancements, alongside data from its diverse portfolio of marketed HIV treatment and . . .